September 2024 – Page 146

Finding Light in the Darkness: Noor Akhter’s Journey of Self-discovery and Inner Strength

Guided by Grace: A True Reflection of the Power of Self-learning

London, UK – September 13, 2024 – Noor Akhter unveils her deeply personal memoir, Guided by Grace, an inspiring tale of resilience, transformation, and the healing power of meditation. This compelling narrative takes readers through Noor’s life, marked by a traumatic childhood, toxic marriages, and the immense challenge of raising three children as a single mother. Adding to that, the book sheds light on a lone parent’s struggle in dealing with a child with mental and health issues, a taboo topic in various parts of the world. Despite these daunting circumstances, Noor’s journey is one of hope, courage, and profound self-discovery.

Guided by Grace stands out not just as a memoir but as a beacon of hope for anyone facing life’s hardships. Noor’s story is a powerful reminder that even in the darkest times, there is a path to a brighter future, and that path, for her, was meditation. This practice became her guiding light, leading her to confront her ego, uncover her true self, and gain the clarity needed to navigate life’s toughest challenges.

Rising Above Utter and Complete Darkness – Noor Akhter’s journey is a testament to the unbreakable human spirit. Despite the overwhelming obstacles she faced, Noor found the strength to rise above her circumstances. Her memoir offers both – the dark and brighter side of resilience, demonstrating how she transformed her pain into a powerful story of endurance and hope.

The Transformative Power of Meditation – Central to Noor’s story is the practice of meditation, which she embraced as a lifeline during her most challenging times. Through meditation, Noor embarked on an inner journey, gaining insights that not only healed her but also empowered her to rebuild her life. Guided by Grace highlights the transformative power of mindfulness, showing readers how to find strength and clarity in their own lives.

A Beacon of Hope for All – Noor’s journey from darkness to light offers universal lessons that resonate with anyone who has faced adversity. Her story is a beacon of hope, encouraging readers to believe in the possibility of a brighter future, no matter how challenging their circumstances may seem.

For those looking for a story that inspires, Guided by Grace provides valuable insights into resilience, self-discovery, and the pursuit of inner peace. Noor Akhter’s memoir is a must-read for anyone seeking to overcome their struggles and find strength within themselves.

Noor Akhter continues to advocate for the transformative power of meditation and mindfulness. She currently resides in the UK, where she is dedicated to empowering others through her story and her ongoing work in mindfulness practices.

For more information, to request a review copy, or to schedule an interview with Noor Akhter.

Media Contact
Company Name: The Empire Publishers UK
Contact Person: Noor Akhter
Email: Send Email
Country: United Kingdom
Website: https://www.theempirepublishers.co.uk/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Finding Light in the Darkness: Noor Akhter’s Journey of Self-discovery and Inner Strength

YMS Expo Propels Beauty & Fashion Industry into New Era

In mid-August, Yimeishang (YMS), under the Yifei Group, successfully held “The 14th 2024 YMS CONSUMER PRODUCTS & CHANNEL EXPO”at the Hangzhou Grand Convention and Exhibition Center.

Bringing together 1000+ exhibitors of trending products, 50,000+ targeted channels and professional visitors, 100+ e-commerce platforms, 500+ industry influencers, and 10,000+ VIP professional buyers from the beauty and fashion industry, the event aimed to seek new opportunities in e-commerce and foster business growth.

Nearly 40,000 Professional Visitors Present

Revealing New Trends and Boosting Industry Development

In 2024, the global beauty and fashion industry is facing even more significant challenges. Root causes include escalating consumer demands, dwindling traffic dividends, rising operational costs, and severe product homogenization, all of which pose new obstacles to growth for beauty and fashion enterprises.

As a global beauty and fashion consumer products industry service platform with over 20 years of expertise, covering over 1 million practitioners in the industry, YMS promptly identified these challenges and organized the “14th YMS CONSUMER PRODUCTS & CHANNEL EXPO.” This expo served as a powerful catalyst, providing inspiration and direction for practitioners navigating new waters and propelling the beauty and fashion industry into a new era of development.

Notably, this was the inaugural event under the new name “YMS CONSUMER PRODUCTS & CHANNEL EXPO” and YMS’s maiden entry into the Hangzhou Grand Convention and Exhibition Center. According to the organizer, the three-day expo attracted 37,206 professional visitors, a testament to its popularity.

Concurrently, six thematic summits were held, including the “New Traffic & New Channels” Global Beauty and Fashion Summit, the Second The Little Red Book KOL Marketing Conference, the Second Channel Live Streaming E-commerce Conference, the Second China Good Product Conference, the First Offline Retail Growth Conference, and the Second Cross-border E-commerce Conference. Over 200 founders and executives of leading companies in the beauty and fashion consumer products industry attended the event, where industry players from supply chains, branding, channels, influencers/MCN agencies, and service providers gathered in this precisely targeted social sphere. From different business perspectives, they spared no effort in sharing their business philosophies and insights into trends, jointly empowering practitioners in the beauty and fashion industry to explore new traffic sources, open up new channels, and achieve new breakthroughs. In the golden age of digital marketing, facing the incremental market built by the Internet, the battle for traffic has already begun.

YMS believes that the industry should return to the consumer frontline. As stated by YMS CEO Qian Qiu, “When we revert to ‘the First Principle Thinking’ and focus on consumers, we can accomplish much.” For instance, optimizing product offerings, live streaming scripts, promotional strategies, studio decorations, and traffic-driving materials in live streaming; refining content materials, images, copywriting, and public-private domain integration in shelf e-commerce; and deepening product development, influencer recommending, and content operations to build brand competitiveness.

Furthermore, multiple events like the Global Influencer Selection, Domestic E-commerce Platform Special Matchmaking Session, Cross-border E-commerce Platform Special Matchmaking Session, and Influencer Investment Matchmaking Session successfully concluded, resulting in over 10,000 cooperation intentions.

Growing with the Times

YMS Becomes an Official Service Provider for The Little Red Book E-commerce Platform

During the 14th YMS Consumer Products Expo, three evenings of celebrations –Founder’s Night jointly sponsored by Hongzhi, TUCO, and Hezhong Group; Beauty and Fashion Night 2024 Industry Awards Ceremony and Social Gala Dinner exclusively sponsored by Inno Aesthetics; and YMS’s 2024 Special Planning: Omnichannel Traffic Awards Ceremony jointly sponsored by GREENLAB and Meiqingxu –c ame to a successful close. These events attracted nearly a thousand participants from across the industry’s supply chain, new consumer brands, beauty brands, online and offline retailers, influencers/MCN agencies, and service providers, with over 1,200 industry awards presented.

Notably, the UK Department for International Trade initiated the formation of the UK Beauty Brand Alliance, aimed at fostering connections between UK brands and Chinese enterprises and consumers while facilitating cooperation and resource sharing between UK and Chinese brands and partners.

As the alliance’s inaugural promotional activity, the UK DIT collaborated with multiple brands to set up a UK Pavilion at the expo, showcasing innovative products in sustainability and natural beauty, including fragrances, skincare, haircare, health supplements, personal care, and makeup.

Moreover, with The Little Red Book’s accelerating commercialization, the platform has emerged as a new growth engine for businesses and brands. Recognizing this trend, YMS has continually adapted to capture new growth opportunities, striving to provide superior services to clients and enable them to grow alongside the times. Consequently, during the Beauty and Fashion Night, an exciting announcement was made–YMS has officially became an official service provider for The Little Red Book E-commerce Platform. An Xi, General Manager of The Little Red Book E-commerce Merchant Development Department, presented the award to YMS, represented by CEO Qian Qiu.

Furthermore, the cross-border trend shone brightly in 2024. During the Southeast Asia segment, YMS honored the most influential KOLs and top MCN agencies from Vietnam, Thailand, Singapore, and Malaysia with the “Most Influential KOL” and “Southeast Asia Elite MCN Agency” awards. Additionally, YMS CEO Qian Qiu, Canadian Trade Commissioner Service’s Commercial Officer Wang Xiaoyi, Inno Aesthetics CMO Zhang Kai, Indonesian celebrity Sarwendah, Vietnamese top livestreamer N.Paia, leading beauty and skincare influencer Blackmilk, acne skincare top blogger Cui Jianan, renowned KOL Li Yang, and renowned channel partner “Dajuan’s Skin Care Home” joined hands to witness the launch of “the YMS Global Treasure New Product Plan.”

Media Contact
Company Name: Yimeishang
Contact Person: Tang Biyu
Email: Send Email
State: Shanghai
Country: China
Website: https://www.yimeishang.com/

Inflammatory Bowel Disease Market Growth Anticipated by 2034 | Companies includes Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead

“Inflammatory Bowel Disease Market”

Factors contributing to this surge include a higher disease burden, significant advances in understanding disease mechanisms, and the development of new diagnostic and therapeutic agents.

The market for Inflammatory Bowel Disease (IBD) is expected to experience substantial growth from 2020 to 2034, as detailed in the latest report titled “Inflammatory Bowel Disease Market Insights, Epidemiology and Market Forecast, 2034” from DelveInsight. This growth is driven by a rise in IBD cases across various regions, which increases the demand for advanced diagnostic and treatment options.

Factors contributing to this surge include a higher disease burden, significant advances in understanding disease mechanisms, and the development of new diagnostic and therapeutic agents. Additionally, improved awareness among physicians, better diagnostic technologies, enhanced healthcare access, and increased patient and physician awareness are also boosting diagnosis rates.

The report provides comprehensive insights into current treatment practices for IBD, emerging drugs in the pipeline, market shares of individual therapies, and the projected market trajectory from 2020 to 2034 across the 7MM (the United States, EU-4 countries—Italy, Spain, France, and Germany—the United Kingdom, and Japan).

Key highlights from the Inflammatory Bowel Disease Market Report:

In 2023, the United States held the largest market share for inflammatory bowel disease (IBD) among the 7MM. The most commonly prescribed treatments for IBD include ASA anti-inflammatory drugs, anti-TNF agents, IL antagonists, JAK inhibitors, TLR 9 agonists, and integrins.
The US was responsible for approximately 50% of the total diagnosed prevalent cases of IBD in the 7MM in 2023, with an anticipated increase in cases during the forecast period from 2024 to 2034. Crohn’s disease, although less common than ulcerative colitis, is generally more severe and is most frequently diagnosed in individuals between the ages of 20 and 30.
In May 2024, Johnson & Johnson announced that it had submitted applications to the European Medicines Agency (EMA) to expand the Marketing Authorization Application for TREMFYA (guselkumab) to include treatment for adult patients with moderately to severely active ulcerative colitis and Crohn’s disease.
Additionally, in October 2023, the US FDA approved OMVOH (mirikizumab-mrkz), the first and only interleukin-23p19 antagonist, for the treatment of moderately to severely active ulcerative colitis in adults.

Driving Forces Behind the Inflammatory Bowel Disease Market Growth

The increasing prevalence of Inflammatory Bowel Disease (IBD) across various regions has led to a greater demand for advanced diagnostic tools and treatment options, driving market expansion. Several factors contribute to rising diagnosis rates, including the growing burden of IBD, substantial progress in understanding its underlying mechanisms, and the development of new diagnostic and therapeutic solutions.

Discover the Anticipated Evolution and Growth of the Market @ Inflammatory Bowel Disease Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Inflammatory Bowel Disease Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2034. Pioneering companies, including Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma, Pfizer, and others, are actively engaged in developing novel drugs for potential market entry.
Inflammatory Bowel Disease Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Inflammatory Bowel Disease. Therapies such as Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz, and others are driving the Inflammatory Bowel Disease market.

Inflammatory Bowel Disease Market Dynamics

Inflammatory Bowel Disease (IBD) currently has no cure, and treatment focuses on alleviating symptoms, preventing complications and flare-ups, and promoting the healing of inflamed intestines. Management strategies for IBD involve a combination of medications, surgical interventions, and lifestyle modifications.

The primary goal of treatment is to stop abnormal inflammation to allow intestinal tissue to heal, which typically relieves symptoms such as diarrhea and abdominal pain. Once symptoms are under control, the focus shifts to reducing flare-ups and maintaining remission. Physicians often start with the least invasive treatments and gradually escalate to more advanced options if necessary.

Currently available medications for IBD include Entyvio (Vedolizumab), a gut-selective biologic from Takeda Pharmaceutical, and Stelara (Ustekinumab) by Janssen Pharmaceuticals, which is approved for adults with moderately to severely active Crohn’s disease and Ulcerative Colitis.

Emerging therapies include Etrolizumab (RG7413), a humanized IgG1 monoclonal antibody targeting the beta-7 integrin subunit, developed by Roche and Genentech. Etrolizumab is undergoing extensive trials with over 3,100 patients across six Phase III studies. Another promising drug is Risankizumab (ABBV-066), an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim for various inflammatory diseases, including Crohn’s disease and Ulcerative Colitis. New therapies such as Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the IBD treatment market during the forecast period.

Learn how the inflammatory bowel disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market

Inflammatory Bowel Disease Treatment Market

The Inflammatory Bowel Disease (IBD) treatment market encompasses pharmaceuticals, therapies, and medical interventions designed to manage and alleviate symptoms of Crohn’s disease and Ulcerative Colitis, the two main forms of IBD. This market includes a range of treatments such as anti-inflammatory drugs, immunosuppressants, biologics, steroids, and, in severe cases, surgical interventions.

As research advances and new insights into IBD emerge, the treatment market continues to evolve with the development of innovative drugs and therapies. Pharmaceutical companies are actively investing in these new treatments to address unmet needs, improve patient outcomes, and enhance quality of life.

The growth of the IBD treatment market is driven by several factors, including the rising global prevalence of the disease, technological advancements, ongoing clinical trials, and a shift towards personalized medicine. The market is highly competitive, with companies focused on creating more effective, targeted therapies to manage symptoms, achieve remission, and prevent progression. Additionally, factors such as patient education, healthcare access, and treatment affordability play crucial roles in shaping the market dynamics.

Leading Inflammatory Bowel Disease Companies and Emerging Drugs: Leading companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma, and Pfizer are actively working on innovative drugs for potential introduction into the Inflammatory Bowel Disease market.

Inflammatory Bowel Disease Therapeutic Landscape: Notable therapies for the treatment of Inflammatory Bowel Disease include Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz, and others.

Inflammatory Bowel Disease Overview:

Inflammatory Bowel Disease (IBD) is a chronic and complex condition caused by immune system dysregulation, influenced by genetic, epigenetic, microbial, and environmental factors. The two primary forms of IBD are Ulcerative Colitis (UC) and Crohn’s Disease (CD), both of which can lead to severe, debilitating symptoms and significant disruptions to daily life.

UC is characterized by the immune system attacking the lining of the intestines, causing chronic inflammation and ulcerations. There is a pressing need for new treatments that effectively alleviate symptoms such as bowel urgency and provide sustained clinical remission.

Crohn’s Disease is a chronic, immune-mediated condition that primarily affects the end of the small intestine (ileum) and the beginning of the colon, though it can involve any part of the gastrointestinal tract from mouth to anus.

Together, UC and CD impact approximately 10 million people globally.

Key Facts Inflammatory Bowel Disease Market Report:

Among the 7MM, the United States holds the largest market size for inflammatory bowel disease. The introduction of new therapies, such as obefazimod, MORF-057, and tulisokibart, is anticipated to drive positive market growth.
The limited treatment options for patients with relapsed or refractory ulcerative colitis present significant opportunities in this therapeutic area.
Factors such as rising prevalence, enhanced diagnostic capabilities, an aging population, advancements in treatment options, increased healthcare spending, growing awareness, and the expansion of healthcare services are expected to contribute to market growth during the forecast period from 2024 to 2034.

Inflammatory Bowel Disease Epidemiology Insights:

In 2023, the United States represented approximately 50% of the total diagnosed cases of Inflammatory Bowel Disease (IBD), including both Crohn’s Disease (CD) and Ulcerative Colitis (UC), across the 7MM. The number of cases in the US is expected to rise during the forecast period.
Within the US, moderate to severe cases of IBD were more prevalent than mild cases in 2023. The 18-44 age group had the highest number of IBD cases in the US.
Among the EU4 countries and the UK, Germany reported the highest prevalence of IBD cases, followed by the UK in 2023.

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Inflammatory Bowel Disease

• Prevalent Cases of Inflammatory Bowel Disease by severity

• Gender-specific Prevalence of Inflammatory Bowel Disease

• Diagnosed Cases oF Inflammatory Bowel Disease

DelveInsight’s comprehensive report provides a thorough exploration of the Inflammatory Bowel Disease market, covering key Inflammatory Bowel Disease players, emerging Inflammatory Bowel Disease therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Inflammatory Bowel Disease Market Outlook 2034

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Bowel Disease Market Growth Anticipated by 2034 | Companies includes Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead

Cervical Dysplasia Market Growth Anticipated by 2034 | Companies includes Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, Trio Lifescience, 3M, Cardinal

“Cervical Dysplasia Market”

In the 7MM, the United States has the highest number of incident cases of Cervical Dysplasia, accounting for approximately 52% of the total. Within this population, around 90% of cases are classified as CIN1.

According to DelveInsight’s latest report, “Cervical Dysplasia Market Insights, Epidemiology and Market Forecast, 2034,” the Cervical Dysplasia market is expected to experience substantial growth from 2020 to 2034. This surge is driven by advancements in both current approved therapies and the anticipated introduction of new treatments between 2023 and 2034. The rising incidence of the condition is also expected to significantly impact the market.

The report provides a comprehensive analysis of current treatment practices, emerging drugs in the pipeline, and the market share of various therapies. It outlines the projected growth trajectory of the Cervical Dysplasia market across the 7MM, which includes the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Key highlights from the cervical dysplasia market report:

In the 7MM, the United States has the highest number of incident cases of Cervical Dysplasia, accounting for approximately 52% of the total. Within this population, around 90% of cases are classified as CIN1.
Treatment approaches for cervical dysplasia vary based on severity. Mild cases may resolve without intervention, but more significant cases generally require surgical treatment, as there are currently no approved disease-modifying therapies. This creates a notable demand for non-surgical alternatives.
To address this gap, pharmaceutical companies such as Frantz Viral Therapeutics are actively working to enhance the treatment landscape for Cervical Dysplasia. Surgery remains the predominant therapy in terms of market size.
The increasing incidence of cervical dysplasia, largely attributed to persistent human papillomavirus (HPV) infection, drives the growing need for both diagnostic and treatment options. In 2023, the United States held the largest market share for Cervical Dysplasia.

Driving Forces Behind the Cervical Dysplasia Market Growth

The cervical dysplasia market is anticipated to expand considerably due to higher screening rates and increased public awareness efforts. However, challenges such as complications associated with current treatments and high costs may negatively affect market growth.

Discover the Anticipated Evolution and Growth of the Market @ Cervical Dysplasia Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Cervical Dysplasia Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2034. Pioneering companies, including Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Lifescience Pvt. Ltd, 3M, Cardinal Health, Cipla Limited, ConvaTec Group PLC, DeRoyal Industries Inc., and others, are actively engaged in developing novel drugs for potential market entry.
Cervical Dysplasia Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Cervical Dysplasia. Therapies such as Gardasil 9, Pembrolizumab, IRX-2, PVX-2, VGX-3100, and others are driving the Cervical Dysplasia market.

Cervical Dysplasia Market Dynamics

The cervical dysplasia market is shaped by several key factors, including advancements in medical technology, improved diagnostic tools, and increased public awareness. Enhanced screening methods and diagnostic technologies have significantly improved early detection and precise evaluation of cervical dysplasia. This progress has driven a demand for less invasive procedures and more personalized treatments.

Increased focus on women’s health, along with vaccination programs targeting high-risk HPV strains, has further heightened the need for regular screenings. Evolving reimbursement policies and a deeper understanding of the disease’s impact are also influencing the market, promoting individualized and patient-centered care.

Despite these advancements, challenges remain, such as limited access to diagnostic tools in underserved areas and stigma around reproductive health issues, which can delay diagnosis. Regulatory hurdles, reimbursement uncertainties, and fluctuations in healthcare policies also impact the adoption of new treatments and the affordability of care.

To address these issues, a multifaceted approach is needed, combining medical innovation with education, advocacy for policy improvements, and efforts to ensure equitable healthcare access. This comprehensive strategy aims to enhance the cervical dysplasia market, making resources more widely available and improving patient outcomes.

Cervical Dysplasia Treatment Market

Choosing a treatment for cervical dysplasia depends on several factors, including the severity of the condition, the patient’s age, overall health, and considerations related to future fertility.

For mild dysplasia (CIN 1), which involves minimal changes in cervical cells, a watchful waiting approach may be recommended. This involves regular Pap smears and HPV tests to monitor if the condition resolves on its own or progresses.

In cases of moderate to severe dysplasia (CIN 2 and CIN 3), more active treatment is usually required. A colposcopy-guided biopsy allows for detailed examination of the cervix. Treatments such as cryotherapy, which freezes and destroys abnormal cells, or Loop Electrosurgical Excision Procedure (LEEP), which uses a heated wire loop to remove affected tissue, may be used. Laser therapy, which vaporizes abnormal cells, is also an option. If dysplasia persists, progresses, or if the patient is older or has completed childbearing, more invasive procedures may be considered. These might include a cone biopsy, which removes a cone-shaped section of the cervix for further analysis, or in severe or recurring cases, a hysterectomy.

Read more about cervical dysplasia and emerging trends @ https://www.delveinsight.com/sample-request/cervical-dysplasia-market

Leading Cervical Dysplasia Companies and Emerging Drugs: Leading companies such as Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Lifescience Pvt. Ltd, 3M, Cardinal Health, Cipla Limited, ConvaTec Group PLC, and DeRoyal Industries Inc., among others, are actively working on developing new drugs for the Cervical Dysplasia market.

Cervical Dysplasia Therapeutic Landscape: Notable therapies for treating Cervical Dysplasia include Gardasil 9, Pembrolizumab, IRX-2, PVX-2, VGX-3100, and others.

Cervical Dysplasia Overview:

Cervical dysplasia is characterized by abnormal cell changes on the surface of the cervix, which is the lower part of the uterus. These abnormalities are commonly identified through screening tests like Pap smears and are often linked to high-risk strains of human papillomavirus (HPV).

Typically, cervical dysplasia does not present any noticeable symptoms and is usually asymptomatic, meaning individuals may not feel any discomfort or physical signs. The abnormal cell changes are often discovered during routine cervical cancer screenings, such as Pap smears or HPV tests, before symptoms develop.

In some cases, especially if cervical dysplasia advances or complications arise, individuals may begin to experience symptoms.

Cervical Dysplasia Emerging Drugs

Artesunate: Frantz Viral Therapeutics

Key Facts Cervical Dysplasia Market Report:

The Cervical Dysplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
In the 7MM, the United States holds the largest market share for cervical dysplasia. Within the EU4 and the UK, Germany and France lead in market share.

Cervical Dysplasia Epidemiology Segmentation:

In 2023, the US reported approximately 1,557,000 new cases of cervical dysplasia. Among the EU4 countries and the UK, France had the highest number of cases, particularly in CIN-1 severity.

The Cervical Dysplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cervical Dysplasia

• Prevalent Cases of Cervical Dysplasia by severity

• Gender-specific Prevalence of Cervical Dysplasia

• Diagnosed Cases oF Cervical Dysplasia

DelveInsight’s comprehensive report provides a thorough exploration of the Cervical Dysplasia market, covering key Cervical Dysplasia players, emerging Cervical Dysplasia therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Cervical Dysplasia Market Outlook 2034

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cervical Dysplasia Market Growth Anticipated by 2034 | Companies includes Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, Trio Lifescience, 3M, Cardinal

Leading Dentiste à Laval: Centre Dentaire Pierre Deslauriers Embraces High Technology to Deliver Comprehensive Dental Care

Centre Dentaire Pierre Deslauriers, a leading dentiste à Laval, offers cutting-edge dental care with advanced technology and personalized treatments for patients of all ages.

Centre Dentaire Pierre Deslauriers continues to offer exceptional dental care, cementing its reputation as a trusted Dentiste à Laval. Combining state-of-the-art technology, personalized patient care, and a team of skilled professionals, the Centre Dentaire Laval ensures a superior experience for every individual seeking dental services.

The Pierre Deslauriers dental clinic provides a full range of dental services for patients of all ages. From preventive care to advanced restorative procedures, the clinic is equipped to meet various dental needs. Routine check-ups, cleanings, and oral health assessments form the foundation of its preventive care approach. This proactive focus helps patients maintain optimal dental health, catching potential issues before they escalate into more serious conditions.

Besides general dentistry, the clinic excels in cosmetic dentistry, offering teeth whitening, veneers, and smile makeovers to enhance patients’ aesthetic goals. The expert team provides precise vital dental services, including crowns, bridges, and dental implants, to repair damaged or missing teeth, ensuring long-lasting solutions that restore function and appearance.

One of the defining features of the dental center is its use of cutting-edge dental technology, improving patient outcomes by enabling precise treatment planning and early detection of problems and reducing the need for invasive procedures.

The clinic is equipped with advanced diagnostic tools, such as digital X-rays and intraoral cameras, allowing for more accurate assessments of oral health conditions. Its CAD/CAM technology also enables same-day restorations for crowns and other dental prosthetics, saving time and providing convenience for busy individuals. Patients also benefit from innovative treatments like laser dentistry, which reduces discomfort and speeds up recovery time.

For more information, visit https://souriredereve.com/

Led by experienced professionals, Centre Dentaire Pierre Deslauriers is well-equipped to handle both routine and complex dental issues. The clinic’s dentists are skilled and stay updated with the latest advancements in the dental field, ensuring patients receive the most current and effective treatments available.

Located in the heart of Laval, Pierre Deslauriers is easily accessible and provides flexible appointment scheduling to accommodate patients with busy lifestyles. With extended hours and emergency services, the clinic offers convenience in addition to top-tier care, ensuring patients receive timely care when needed.

Centre Dentaire Pierre Deslauriers stands out for its commitment to patient care. Recognizing the anxiety commonly associated with dental visits, the clinic prioritizes creating a comfortable, welcoming environment for all patients. Comprising a team of exceptional hygienists, dental assistants, and administrative staff, the clinic provides support at every step to ensure a seamless experience.

This collaborative approach allows the clinic to function efficiently and maintain high standards of care. The clinic fosters deep dentist-patient relationships, building trust with honest and open discussions to help patients make informed decisions about their dental care. Patients are fully informed about their oral health, treatment options, and associated costs, making Centre Dentaire Pierre Deslauriers a trusted name in the Laval community.

As an integral part of its service, the clinic actively promotes the importance of oral hygiene through patient education. Helping individuals understand how to care for their teeth and gums at home will prevent dental issues and promote long-term oral health.

Centre Dentaire Pierre Deslauriers has established its reputation as a premier dental clinic in Laval through its comprehensive services, commitment to advanced technology, and patient-first philosophy. With a legacy of service excellence in the community, the clinic continues to make strides in delivering high-quality dental care, making it the go-to destination for all dental needs in the area.

About Centre Dentaire Pierre Deslauriers:

Centre Dentaire Pierre Deslauriers, located in Laval, Quebec, offers a full spectrum of dental services that prioritize patient comfort and personalized care, from preventive care to advanced cosmetic and restorative procedures. Equipped with cutting-edge tools and supported by a team of experienced professionals, the clinic ensures precise and efficient treatments that foster long-term relationships built on trust and transparency. Emphasizing oral health education and the latest technology, Centre Dentaire Pierre Deslauriers is a premier destination for comprehensive dental care in the Laval community.

Media Contact
Company Name: Centre Dentaire Pierre Deslauriers
Contact Person: Pierre Deslauriers
Email: Send Email
Phone: 1-450-668-9220
Address:1421 Boul. de l’Avenir
City: Laval
State: QC H7N 6G4
Country: Canada
Website: https://souriredereve.com/

New Braunfels Roofing Company: Roof Repair, Replacement, and Installation by Lunar Roofing Solutions LLC

Lunar Roofing Solutions LLC, a licensed and insured roofing company in New Braunfels, TX, offers top-tier roofing services, including repair, installation, and replacement, tailored to meet the needs of local homeowners and businesses. The firm uses high-quality materials, competitive pricing, and unmatched customer service.

Lunar Roofing Solutions LLC, led by industry veteran Elias Renteria, continues to set the standard for reliable, high-quality roofing services in New Braunfels and surrounding areas. As a licensed, insured, and manufacturer-certified roofing company, Lunar Roofing provides comprehensive services such as roof repair, replacement, and installation, all designed to meet the unique needs of local homeowners and businesses.

A company representative says, “Our goal is to ensure every roof we work on is durable, energy-efficient, and visually appealing. We understand that a roof is a vital part of protecting a property against the harsh Texas weather. That’s why we use only the best materials and cutting-edge techniques.”

Lunar Roofing Solutions specializes in a range of services, from repairing damaged shingles and leaky roofs to full roof replacements with energy-efficient materials. The company also handles new roof installations for both residential and commercial properties, gutter installation and cleaning, as well as siding and window installation and repair.

The company’s commitment to high-quality craftsmanship ensures long-lasting results, whether it’s a minor repair or a complete roof overhaul. By working closely with clients, Lunar Roofing tailors each project to fit their budget, style preferences, and specific needs, making top-notch roofing solutions accessible through competitive pricing and flexible financing options.

Additional details are available at http://lunarroofingtx.com/

Lunar Roofing Solutions prides itself on being a trusted local provider, offering in-depth knowledge of New Braunfels, San Marcos, and surrounding communities. This local expertise allows the company to recommend the best materials and solutions that suit the specific climate and environmental challenges of Central Texas. “Our clients can count on us for personalized service,” said the representative. “From selecting materials to project completion, we prioritize transparency and collaboration, ensuring the final result is exactly what they envisioned.”

To further support property owners, Lunar Roofing offers customizable maintenance plans to extend the life of each roof and avoid costly repairs in the future. This proactive approach helps homeowners and businesses maintain secure, energy-efficient, and visually appealing properties year-round.

With decades of combined experience in the roofing industry, Lunar Roofing Solutions has earned a reputation as the premier choice for roofing services in New Braunfels. The company is known for delivering exceptional results on time and within budget, emphasizing integrity, superior workmanship, and a client-first mindset.

“Choosing the right roofing contractor is a critical decision for any property owner,” the company representative added. “At Lunar Roofing, we combine expertise with personalized service, ensuring every project we take on exceeds expectations.”

For property owners looking to upgrade their roofs or address specific issues like leaks or weather damage, Lunar Roofing Solutions is ready to provide a free, no-obligation consultation.

About the Company:

Based in New Braunfels, TX, Lunar Roofing Solutions LLC serves residential and commercial property owners throughout Central Texas. The company’s focus on customer service, high-quality materials, and innovative techniques has made it a trusted name in the roofing industry. With a strong commitment to professionalism, integrity, and community involvement, Lunar Roofing Solutions aims to provide the best possible roofing solutions to its clients.

Media Contact
Company Name: Lunar Roofing Solutions LLC
Contact Person: Elias Renteria
Email: Send Email
Phone: 830-800-0252
Address:2055 Central Plaza Ste 110 #321
City: New Braunfels
State: TX 78130
Country: United States
Website: https://lunarroofingtx.com/

Windfree Solar Welcomes Joseph Clair as Vice President of Commercial and Industrial Projects

Windfree Solar is thrilled to announce the addition of Joseph Clair as the Vice President of Commercial and Industrial Projects. With over three decades of experience in building design and operations, Joseph brings a wealth of knowledge and passion for sustainable energy solutions to our team.

Joseph’s career has been marked by significant contributions to the green building movement. A key figure in the founding of the Illinois chapter of the U.S. Green Building Council, Joseph has been at the forefront of initiatives aimed at reducing the environmental impact of buildings. His deep commitment to sustainability is evident in his work with Chicago Public Schools, where he played a pivotal role in developing green building standards that led to the creation of 24 new certified green schools, pushing the boundaries of energy efficiency.

At Windfree Solar, Joseph has been overseeing the delivery of commercial and industrial projects. He’s amazing at ensuring that our solar energy solutions are not only cutting-edge but also practical and achievable for our clients. His focus on maximizing and right-sizing solar installations will help us continue to lead the way in the development of net-zero energy buildings.

“I’ve worked very hard on the building design and operations side of things. Now I’m really excited to get into making these buildings zero energy through solar, further driving the design community to really step up and make buildings fit within the energy that’s available to them on their sites.” – Joseph Clair

With Joseph Clair’s appointment, Windfree Solar gains a seasoned professional who has been a driving force in the green building movement. His passion for sustainability, technical expertise, and leadership skills position him to make significant contributions to the company’s commercial and industrial solar projects. Windfree Solar is confident that Joseph’s addition will further strengthen its position as a leader in delivering innovative, practical solar energy solutions.

Outside of work, Joseph is an avid skier, theater enthusiast, and lifelong learner who values work-life balance. His philosophy resonates with the company culture, and Windfree Solar is confident that Joseph’s leadership will inspire the team to reach new heights.

Windfree Solar is excited to welcome Joseph Clair and looks forward to the positive impact he will have on the company and the communities it serves.

Media Contact
Company Name: Windfree Solar
Contact Person: Brittany Brilliant
Email: Send Email
Phone: (312) 588-6953
Address:5022 W Foster Ave
City: Chicago
State: IL 60630
Country: United States
Website: https://windfree.us/

KAYAK reveals 1 in 4 Brits now seeking a Sleepcation: New study crowns Sligo, Ireland as the ultimate Sleep Tourism destination

• KAYAK launches Sleep Tourism Guide for travellers, as new research reveals 1 in 4 Brits are prioritising sleep-focused getaways

• Sligo, Ireland, Kyoto, Japan and Funchal, Portugal take the top three spots for “sleepcations” according to new study

• Guide created in collaboration with Sleep Scientist Dr. Jason Ellis, reveals the top 50 destinations for sleep tourism alongside useful tips for optimising sleep on holiday

13 SEPTEMBER, 2024 – LONDON, UK – As new research finds 1 in 4 Brits are now considering booking a holiday focussed primarily on sleep, KAYAK, the world’s leading travel search engine, has launched its new Sleep Tourism Guide for tired Brits in need of a restful escape, with Sligo, Ireland coming out on top as the ultimate ‘sleepcation’ destination.

KAYAK’s new Sleep Tourism Guide comes in response to a desire for sleep tourism in the UK, where travellers seem to continuously prioritise rest and relaxation as key components of their holiday experience, as supported by new insights from the travel search engine:

2 in 5 (39%) put R&R top of their holiday requirements this year
One third (39%) of Brits finds they return from holiday in need of another holiday
Over half (53%) of travellers report better sleep quality on holiday

To develop the guide, KAYAK, in collaboration with Sleep Scientist Dr. Jason Ellis, analysed the most searched destinations for accommodations, worldwide, on KAYAK.co.uk and scored them against their potential for enhancing sleep quality. The guide evaluates key factors including air quality, noise pollution, political stability, proximity to nature, as well as access to accommodation with spa amenities and accommodation prices. Ultimately, revealing the top 50 destinations for British travellers seeking to optimise their sleep while on holiday.

Sleep Expert, Dr Jason Ellis, commented, “It’s clear from KAYAK’s new research that we’re sleep deprived as a nation. ‘Sleepcation’ holidays are a great way to pay off some of the ‘sleep debt’ we experience in daily life. By choosing the right destinations that excel in factors that contribute to better sleep, travellers can maximise their rest and return home feeling truly rejuvenated.”

The top ranked sleepcation destination from the analyses goes to Sligo, Ireland. The sleepy coastal destination on Ireland’s beautiful west coast balances an impressively good air quality and political stability score with low noise pollution, along with a wide range of accommodation featuring spa and wellness amenities. It’s the perfect destination for optimising your sleep. Kyoto, Japan and Funchal, Portugal also scored well across these categories, earning the second and third spot on the list.

Dreamy escapes: KAYAK’s top 10 sleepcation destinations
Destination ranking	Avg. accommodation price	Air Quality Index	% of accommodation on KAYAK with spas	Noise pollution (dB)	Political Stability & Governance	Final Score / 100
1. Sligo, Ireland	£130	28	14%	7	79	100
2. Kyoto, Japan	£126	32	9%	22	87	91
3. Funchal, Portugal	£135	46	10%	15	76	87
4. Zadar, Croatia	£105	25	5%	22	67	84
5. Split, Croatia	£137	31	5%	17	67	83
6. Auckland, New Zealand	£81	36	14%	45	96	83
7. Letterkenny, Ireland	£124	28	13%	31	79	83
8. Lagos, Portugal	£128	21	8%	30	76	82
9. Puerto de la Cruz, Spain	£112	32	6%	17	53	80
10. Bridgetown, Barbados	£244	28	11%	27	92	80

See the full ranking on KAYAK here: www.kayak.co.uk/news/sleep-tourism-guide

The shift to more restful escapes is also reflected in KAYAK’s recent search data. The travel search engine’s analysis of the top trending destinations for autumn travel signals a growing preference towards nature-focused getaways and coastal retreats, with flight searches for destinations like Tromsø, Norway, Koh Samui, Thailand, and Thiruvananthapuram, India amongst the top list, with flight searches up 74%, 49%, 36% and compared to last year, respectively.

Rachel Mumford, KAYAK UK Travel Expert commented, “From constant digital distractions to the fast-paced demands of everyday life, we believe more Brits are turning to more relaxing, sleep-focused holidays as a form of self-care. That’s why we launched the Sleep Tourism Guide — to provide travellers with the info they need to find the best destinations to rest and recharge.”

To view the full ranking alongside Dr. Ellis’ expert advice on optimising sleep while travelling, check out KAYAK’s Sleepcation Guide: www.kayak.co.uk/news/sleep-tourism-guide.

Notes to Editors

Sleep Like a Pro: 5 Tips for Better Rest While Travelling, according to Dr. Ellis:

Mind your diet: Opt for foods with sleep promoting effects that will help you wind down. One of Dr. Ellis’ favourites is kiwis which contain polythene, an ingredient that promotes mild sedative effects. To get the best slumber during your trip, start eating two kiwis after dinner, three days before you travel.
Sleeping material: When choosing your stay, check out the accommodation’s information on linens and curtains (often found in the provider’s photos or the “about” section when searching on KAYAK). Blackout curtains are perfect for minimising the effects of light pollution on your sleep.
Morning sun: Exposure to the sun shortly after waking up via a morning walk or having breakfast outdoors supports in naturally adjusting your body clock.
Try a “nappuccino”: If you need to nap when you arrive at your destination, try drinking a cup of coffee right before taking a 20 minute nap. The caffeine kicks in just as you wake up, combining the restorative effects of a short nap with an extra boost of alertness.
Apply 90/20 rule for daily activities: Just like we have a night rhythm we also have a daytime one. Abide by the 90/20 rule – 20 minutes of downtime for every 90 minutes of activity – to promote better sleep in the evening.

About KAYAK

KAYAK, part of Booking Holdings (NASDAQ: BKNG), is the world’s leading travel search engine. With billions of searches on our platforms, we help people find their perfect flight, accommodation, car rental and holiday package. We also support business travellers with our corporate travel solution.

About Jason Ellis:

Jason Ellis is Professor in Psychology at Northumbria University and Director of the Northumbria Centre for Sleep Research. He has sat on various committees including the British Psychological Society – Division of Health Psychology, the Teaching and Educational Advisory Committee for the Sleep Research Society (based in the USA) and the Division of Health Psychology Scotland.

Sleep Tourism Ranking Methodology:

KAYAK considered the most clicked-on accommodation city destinations worldwide based on clicks made on KAYAK.co.uk from the 1st January 2024 to 31st July 2024 for the travel period between 7th January 2024 and 31st December 2024. These cities were then shortlisted based on their proximity to natural landmarks such as: mountains, lakes, rivers, beaches, hot springs and national parks. These shortlisted destinations were subsequently analysed against the following key factors: air quality, noise pollution, political stability and governance, access to accommodation with spa amenities, and accommodation prices. For full methodology, visit www.kayak.co.uk/news/sleep-tourism-guide

KAYAK Data Methodology:

Based on flight searches made on Kayak.co.uk in the period between 02/14/2024 – 14/08/2024 for flights with departure between 15/09/2024 – 30/11/2024 from any UK airport. They were compared to the same search and travel period one year prior. Percentages for changes in searches are approximate.

Survey Methodology:

An online survey was conducted by PureSpectrum targeting 2020 respondents across the UK who had ever been on holiday, either domestically or internationally, within the last two years. The data was collected between 14th – 18th March 2024.

Media Contact
Company Name: Kayak
Contact Person: Media Relations
Email: Send Email
Country: United Kingdom
Website: http://johndoehub.com

Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

“Chronic Constipation Market”

The significant growth of the chronic constipation market is driven by a combination of factors, including advancements in treatment innovations, shifting demographic trends, and evolving therapeutic approaches.

The market for chronic constipation is expected to experience substantial growth from 2019 to 2032, as detailed in the latest report, “Chronic Constipation Market Insights, Epidemiology, and Market Forecast, 2032” by DelveInsight. This growth is driven by advancements in both existing therapies and new treatments scheduled for release between 2023 and 2032, coupled with a rising incidence of the condition.

The report provides comprehensive insights into current treatment practices for chronic constipation, details on emerging drugs in the pipeline, market shares of various therapies, and forecasts for market trends from 2019 to 2032 across the 7MM (the United States, the EU-4 including Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Chronic Constipation Market Growth

Discover the Anticipated Evolution and Growth of the Market @ Chronic Constipation Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Chronic Constipation Clinical Trial Progression: The market is poised for substantial growth, fueled by the introduction of new therapies anticipated to launch between 2023 and 2032. Leading companies such as Kissei Pharmaceutical Co., Ltd., Wecare Probiotics Co., Ltd., and Astellas Pharma Inc., among others, are actively working on developing innovative drugs for potential entry into the market.
Chronic Constipation Innovative Therapies: Ongoing research and development efforts are driving the creation of innovative therapies aimed at addressing the symptoms of chronic constipation. Emerging treatments such as Naronapride, Linaclotide, KWA-0711, ASP0456, Tegaserod, AJG555, RM-131, Prucalopride, TD-5108, PEG 4000, Lubiprostone, and others are showing promising results in clinical trials.

Leading Chronic Constipation Companies and Emerging Drugs: Leading companies such as Kissei Pharmaceutical Co., Ltd., Wecare Probiotics Co., Ltd., and Astellas Pharma Inc., among others, are actively working on developing new drugs for potential entry into the chronic constipation market.

Chronic Constipation Therapeutic Landscape: Key therapies for treating chronic constipation include Linaclotide, KWA-0711, ASP0456, Tegaserod, AJG555, RM-131, Prucalopride, TD-5108, PEG 4000, Lubiprostone, Naronapride, and others.

Chronic Constipation Overview:

Chronic constipation is a prevalent digestive disorder marked by infrequent bowel movements and difficulty passing stool. Unlike occasional constipation, which is temporary and typically resolves on its own, chronic constipation is a long-term condition that persists for several weeks or more. Symptoms often include fewer than three bowel movements per week, straining during defecation, and hard, lumpy stools.

Common causes of chronic constipation include:

– Slow Stool Movement: Reduced motility through the colon

– Dietary Factors: Low fiber intake from fruits and vegetables

– Inadequate Fluid Intake: Leading to dehydration

– Lack of Exercise: Contributing to slowed digestion

– Medical Conditions: Such as irritable bowel syndrome (IBS) or other gastrointestinal disorders

– Medication Side Effects: From drugs like opioids or certain antidepressants

– Mental Health Issues: Including stress, anxiety, and depression

– Eating Disorders: Impacting digestive function

Diagnosis of chronic constipation involves a thorough assessment, including:

– Medical History Review: To understand the patient’s symptoms and history

– Physical Examination: To identify any physical abnormalities

– Diagnostic Tests: Such as blood tests to rule out underlying conditions, and imaging studies like X-rays or colonoscopy to evaluate the colon’s structure and detect any abnormalities

This diagnostic process can be challenging due to factors such as symptom underreporting, overlap with other gastrointestinal disorders, the absence of definitive diagnostic tests, and the lack of standardized criteria. Consequently, a comprehensive evaluation by healthcare professionals is essential.

Management of chronic constipation follows a stepwise approach:

1. Initial Assessment: Identifying and addressing secondary causes and underlying conditions

2. Lifestyle and Dietary Changes: Implementing fiber-rich diets and increasing fluid intake, along with behavioral modifications

3. Laxative Use: If lifestyle changes are ineffective, options include bulk-forming, osmotic, and stimulant laxatives

4. Prokinetic Agents: For persistent symptoms, medications like prucalopride may be prescribed

5. Biofeedback Therapy: Recommended for patients with defecation disorders

6. Surgical Intervention: Considered only as a last resort after all other treatment options have been exhausted

Chronic Constipation Epidemiology Segmentation:

According to Yamamoto et al. (2022), an online survey conducted in the US found that the prevalence of chronic constipation was 5.5% based on the Rome III criteria, whereas in Japan, it was 2.1% based on medical consultations.
The Comprehensive Survey of Living Conditions in Japan (2017) indicated that constipation is more common in women than men. However, the prevalence among men increases significantly after age 70, with nearly equal rates observed at age 80 and older.
Roque and Bouras (2015) found that the cumulative incidence of chronic constipation is approximately 20% in the elderly, significantly higher than in younger populations. Severe constipation is particularly prevalent in older women, occurring at rates two to three times higher than in their male counterparts.
Enck et al. (2015) reported that global prevalence rates for chronic constipation vary widely, ranging from 2.4% to 35%, with Germany showing a lower rate of 5%.
Shin (2021) highlighted that chronic constipation leads to about 1 million hospital visits annually in the US and forecasted an increase in prevalence due to an aging population.
Given the higher rates of chronic constipation in older adults, the prevalence is expected to rise as the global population ages. This trend underscores the growing need for effective management strategies and interventions to address this increasing health issue.

The Chronic Constipation market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Chronic Constipation

• Prevalent Cases of Chronic Constipation by severity

• Gender-specific Prevalence of Chronic Constipation

• Diagnosed Cases Chronic Constipation

Chronic constipation Marketed Drugs

LINZESS (linaclotide): ABBVIE
GOOFICE: Eisai Co., Ltd.

Chronic Constipation Emerging Drugs

ANJ908 (Pradigastat): Anji Pharma
YH12852: Yuhan

Chronic Constipation Market Outlook

Various treatment options are available for chronic constipation, including over-the-counter laxatives, prescription medications, dietary changes, and lifestyle adjustments. With the global rise in chronic constipation cases, the demand for these treatments is anticipated to remain high. Fiber supplements have proven effective in improving functional constipation.

Current literature suggests that osmotic and stimulant laxatives should be the first line of treatment for chronic constipation. Polyethylene glycol (PEG) 3350, known for its substantial osmotic activity, is effective for short-term relief and is available over the counter for occasional constipation.

Linaclotide, marketed as LINZESS, works as an agonist of the Heat Stable Enterotoxin Receptor (Guanylyl Cyclase C). Approved in 2012, it is now available worldwide, including in the US, the UK, France, Germany, China, and Japan, through Allergan Sales LLC.

Lubiprostone, approved by the FDA in January 2006, is used to treat chronic constipation and IBS-C based on clinical studies demonstrating its safety and efficacy.

Prucalopride, marketed as Resolax or Montegrity, is a prescription medication for chronic idiopathic constipation (CIC) in patients who have not found relief from laxatives.

For patients unresponsive to medical treatments, surgical interventions may be considered, including mechanical colon emptying with enema programs for those with slow bowel movements.

Ongoing research is focused on developing novel therapies to address the unmet needs in chronic constipation. Pharmaceutical companies are investing in new treatments aimed at normalizing gut transit, enhancing bowel function, stimulating gut motility, and promoting intestinal secretion.

According to DelveInsight, significant changes are expected in the Chronic Constipation market across the 7MM from 2019 to 2032.

For in-depth insights, access the full report @ Chronic Constipation Market Outlook 2032

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

Professional Headshots Sydney: Elevating Personal Branding with Sydney Headshots by Nicholas Ditsas

Sydney Headshots by Nicholas Ditsas offers expert professional headshots, helping individuals enhance their branding with polished, high-quality headshots that make lasting impressions.

While the rise of smartphone cameras and DIY photography makes it tempting to take headshots on a personal device, the value of a professionally taken headshot cannot be overstated. Highly acclaimed photographer of professional headshots Sydney, Nicholas Ditsas, brings his artistic and technical skillset to every shoot, ensuring clients receive images that stand out.

Operating out of Redfern, Sydney Headshots is a leading photography studio. Founded and led by Nicholas Ditsas, the studio has built a reputation for excellent corporate and personal branding images, creating high-quality, striking headshots that convey confidence, approachability, and professionalism.

Often the first visual representation seen in a professional setting, these headshots are perfect for use in corporate profiles, social media platforms, and personal websites, where first impressions are critical. With personal branding becoming more important than ever, having a high quality polished headshot can set an individual apart in competitive industries.

With over 13 years of industry experience, Nicholas Ditsas combines his extensive experience with a personal touch to make every session comfortable and effective. From corporate executives to creative professionals, this headshot photographer in Sydney leverages his unique approach to deliver impeccable photos to project the persona that aligns with the client’s brand and career goals.

“At Sydney Headshots, we are dedicated to helping businesses and professionals take control of their online presence, offering a highly specialised service for individuals and businesses, looking to elevate their professional image. A great headshot is more than just a photo—it’s a powerful personal and professional branding tool. We work closely with each client to capture their best angles and coach authentic expressions considering key elements like lighting, angles, composition, and facial expression,” said Ditsas.

For more information, visit https://www.sydney-headshots.com/

As a professional photographer in Sydney, Nicholas Ditsas has built a reputation for delivering high-quality portraits that enhance personal branding. His extensive knowledge in portrait photography, combined with a keen eye for detail, allows him to capture the essence of each subject in an authentic and flattering manner. He works closely with clients to understand their goals, ensuring that the final image reflects their individuality and professionalism.

Sydney Headshots by Nicholas Ditsas offers a tailored experience for each client, ensuring that every session meets its specific needs. From corporate headshots to creative and artistic portraits, Nicholas delivers consistent results that help clients put their best foot forward. His relaxed yet professional demeanor during the photoshoot creates an environment where clients feel comfortable, resulting in natural and expressive headshots.

The studio provides a fully customized photography experience, considering every detail carefully to create the perfect headshot. From guidance on wardrobe selection to posing and styling, Ditsas helps clients project their personality through body language and facial expressions, ensuring the final images are both natural and impactful.

Post-session, the images are meticulously edited, paying close attention to details like skin tone, lighting, and sharpness. This post-production process enhances the photographs while maintaining the integrity of the client’s appearance, resulting in images that are clean, professional, and ready for use across various platforms.

With a commitment to excellence and a keen understanding of the power of personal branding, Nicholas Ditsas continues to lead the industry in professional headshot photography in Sydney. Those seeking to elevate their personal or professional image will find that a session with Nicholas is an investment that pays off with long-term branding success.

About the Studio:

Sydney Headshots is a premier photography studio specialising in professional headshots for corporate and creative professionals. Known for delivering high-quality, polished images to enhance personal branding, Nicholas Ditsas combines the key elements of lighting, composition, and expression to create striking portraits that convey confidence and professionalism. With a tailored approach to each client, Nicholas ensures that every photo session results in natural, impactful images that reflect the individual’s personality and goals. Sydney Headshots is the go-to choice for professionals seeking exceptional headshot photography in Sydney.

Media Contact
Company Name: Sydney Headshots
Contact Person: Nicholas Ditsas
Email: Send Email
Phone: +61424286202
Address:103 Regent St
City: Redfern
State: NSW 2016
Country: Australia
Website: https://www.sydney-headshots.com/